JP2002543151A5 - - Google Patents

Download PDF

Info

Publication number
JP2002543151A5
JP2002543151A5 JP2000615040A JP2000615040A JP2002543151A5 JP 2002543151 A5 JP2002543151 A5 JP 2002543151A5 JP 2000615040 A JP2000615040 A JP 2000615040A JP 2000615040 A JP2000615040 A JP 2000615040A JP 2002543151 A5 JP2002543151 A5 JP 2002543151A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
antibody
composition according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000615040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/012041 external-priority patent/WO2000066156A1/en
Publication of JP2002543151A publication Critical patent/JP2002543151A/ja
Publication of JP2002543151A5 publication Critical patent/JP2002543151A5/ja
Pending legal-status Critical Current

Links

JP2000615040A 1999-05-04 2000-05-04 死ドメイン含有レセプター5 Pending JP2002543151A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13249899P 1999-05-04 1999-05-04
US13323899P 1999-05-07 1999-05-07
US14893999P 1999-08-13 1999-08-13
US60/148,939 1999-08-13
US60/132,498 1999-08-13
US60/133,238 1999-08-13
PCT/US2000/012041 WO2000066156A1 (en) 1999-05-04 2000-05-04 Death domain containing receptor 5

Publications (2)

Publication Number Publication Date
JP2002543151A JP2002543151A (ja) 2002-12-17
JP2002543151A5 true JP2002543151A5 (cg-RX-API-DMAC10.html) 2007-05-31

Family

ID=27384298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000615040A Pending JP2002543151A (ja) 1999-05-04 2000-05-04 死ドメイン含有レセプター5

Country Status (5)

Country Link
EP (1) EP1196191A4 (cg-RX-API-DMAC10.html)
JP (1) JP2002543151A (cg-RX-API-DMAC10.html)
AU (1) AU4817200A (cg-RX-API-DMAC10.html)
CA (1) CA2369371A1 (cg-RX-API-DMAC10.html)
WO (1) WO2000066156A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
KR100932577B1 (ko) * 2001-05-18 2009-12-17 기린 홀딩스 가부시키가이샤 항 trail-r 항체
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
EP1439225A4 (en) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co DR5-GEN PROMOTER AND SIAH-1-GEN PROMOTER
WO2004085479A2 (en) * 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2005114187A2 (en) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 The Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
WO2013148877A1 (en) * 2012-03-28 2013-10-03 Amgen Inc. Dr5 receptor agonist combinations
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
NZ508381A (en) * 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
WO2000073349A1 (en) * 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Similar Documents

Publication Publication Date Title
US20250313634A1 (en) Novel anti-pd-l1 antibodies
JP4764627B2 (ja) 新生物疾患又は免疫不全を処置するためのヒト化免疫調節性モノクローナル抗体
AU2001295490B2 (en) Antibodies to human IL-1beta
JP5179689B2 (ja) 抗体ベース融合タンパク質の循環系内半減期の増強
US7771723B2 (en) Remedies for myeloma to be used together with nitrogen mustard antitumor agents
EP0633931B1 (en) Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
US20180162944A1 (en) Novel anti-pd-l1 antibodies
CN112552399B (zh) 抗sars-cov-2中和抗体
JP2002544172A5 (cg-RX-API-DMAC10.html)
JP2022536114A (ja) 抗ceacam5モノクローナル抗体およびその調製方法およびその使用
CN111494626A (zh) 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
EP1470159A2 (en) Antibody to latent membrane proteins and uses thereof
WO2011137687A1 (zh) 一种抗癌胚抗原抗体及其应用
CN106243225A (zh) 新型抗-pd-l1抗体
EP1159003B1 (en) Anti-tnf alpha antibodies in therapy of steroid resistant asthma
CN121263449A (zh) Cd19/cd38多特异性抗体
CA2240834C (en) Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US8679483B2 (en) High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
US12583935B2 (en) Anti-human CD47 antibody and antigen-binding fragment thereof, and preparation method therefor and use thereof
CN114409766B (zh) 一种eb病毒的中和性抗体及其应用
CA2199940C (en) Anti-receptor and growth blocking agents to the vitamin b12/transcobalamin ii receptor and binding sites
Xiang et al. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells
CN116063512B (zh) 多功能重组抗体及其制备方法和应用
US20050169910A1 (en) Growth blocking agents
KR20250127148A (ko) 항-인터류킨-6 항체 투여에 의한 심근염의 치료